Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Travoprost Intraocular Implant + iStent Infinite

NCT: NCT06066645 · RECRUITING

NCT IDNCT06066645
StatusRECRUITING
Start Date2023-09-14
Completion2028-02
SponsorGlaukos Corporation (INDUSTRY)
First posted
Last updated

Brief Summary

Adult subjects with elevated intraocular pressure will be randomized to receive iStent infinite trabecular bypass system plus a travoprost intraocular implant or receive a sham procedure plus a travoprost intraocular implant and be followed for 12 months.

Frequently Asked Questions

What is Travoprost Intraocular Implant + iStent Infinite?

Travoprost Intraocular Implant + iStent Infinite is a clinical trial registered under NCT06066645. Current status: RECRUITING.

What is the status of NCT06066645?

The current status of NCT06066645 (Travoprost Intraocular Implant + iStent Infinite) is: RECRUITING.

When did Travoprost Intraocular Implant + iStent Infinite start?

Travoprost Intraocular Implant + iStent Infinite started on 2023-09-14.

Related Devices

K220032iStent infinite Trabecular Micro-Bypass System, Model iS3Glaukos Corporation PMA P080030Intraocular pressure lowering implantGlaukos Corporation PMA P170043Intraocular pressure lowering implantGlaukos Corporation K212797iPrime Viscodelivery SystemGlaukos

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑